The present studies provide compelling evidence that enhanced ASMase activation via timely applied antiangiogenic drug therapy may serve as a radiosensitizing “bio-booster” of PMDS, enabling 5–8 Gy left shift of the SDRT dose-response curve, potentially decreasing the PMDS/OAR interaction from 18 Gy to < 14 Gy and thereby resolving a large fraction of current intractable tumor/OAR settings. This evidence concerns the gene SMPD1 and neoplasm.